AR052959A1 - Anticuerpos anti- ccr5 y usos de los mismos - Google Patents
Anticuerpos anti- ccr5 y usos de los mismosInfo
- Publication number
- AR052959A1 AR052959A1 ARP060101255A ARP060101255A AR052959A1 AR 052959 A1 AR052959 A1 AR 052959A1 AR P060101255 A ARP060101255 A AR P060101255A AR P060101255 A ARP060101255 A AR P060101255A AR 052959 A1 AR052959 A1 AR 052959A1
- Authority
- AR
- Argentina
- Prior art keywords
- num
- group
- same
- cdr1
- cdr2
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Transplantation (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Un anticuerpo que se une al CCR5 humano formado por una cadena pesada variable y una cadena ligera variable, que se caracteriza en que la cadena pesada variable consta de las secuencias CDR, CDR1, CDR2 y CDR3 y siendo la CDR1 seleccionada de un grupo formado por los ID. DE SEC. NUM: 9, 10, 11, 12; siendo la CDR2 seleccionada del grupo formado por los ID. DE SEC. NUM: 13, 14, 15; y siendo la CDR3 seleccionada de un grupo formado por los ID DE SEC NUM: 16, 17, donde dichas CDR se seleccionan independientemente de cada una o es variante humanizada, quimérica o un fragmento de dicho anticuerpo y tiene unas propiedades ventajosas para el tratamiento de las enfermedades inmunosupresoras.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05007138 | 2005-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR052959A1 true AR052959A1 (es) | 2007-04-11 |
Family
ID=34934663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060101255A AR052959A1 (es) | 2005-04-01 | 2006-03-30 | Anticuerpos anti- ccr5 y usos de los mismos |
Country Status (19)
Country | Link |
---|---|
US (1) | US7615216B2 (es) |
EP (2) | EP1869087A2 (es) |
JP (2) | JP4733736B2 (es) |
KR (1) | KR20070116136A (es) |
CN (1) | CN101175771A (es) |
AR (1) | AR052959A1 (es) |
AU (1) | AU2006228663A1 (es) |
BR (1) | BRPI0609792A2 (es) |
CA (1) | CA2603692A1 (es) |
CR (1) | CR9393A (es) |
IL (1) | IL186071A0 (es) |
MA (1) | MA29374B1 (es) |
MX (1) | MX2007011842A (es) |
NO (1) | NO20074867L (es) |
RU (1) | RU2007139953A (es) |
SG (1) | SG151284A1 (es) |
TW (1) | TW200720289A (es) |
WO (1) | WO2006103100A2 (es) |
ZA (1) | ZA200708332B (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101410414A (zh) * | 2006-01-30 | 2009-04-15 | 弗·哈夫曼-拉罗切有限公司 | 用于治疗hiv的具有协同作用的组合物 |
TW200817438A (en) | 2006-08-17 | 2008-04-16 | Hoffmann La Roche | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
MX2009002694A (es) | 2006-09-29 | 2009-03-24 | Hoffmann La Roche | Anticuerpos dirigidos contra ccr5 y usos de los mismos. |
US20090143288A1 (en) | 2007-03-13 | 2009-06-04 | Roche Palo Alto Llc | Peptide-complement conjugates |
US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
EP2235061A1 (en) * | 2008-01-15 | 2010-10-06 | F. Hoffmann-La Roche AG | Afucosylated antibodies against ccr5 and their use |
WO2010028798A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
WO2010028796A1 (en) * | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
JP2012513425A (ja) | 2008-12-22 | 2012-06-14 | エフ.ホフマン−ラ ロシュ アーゲー | 免疫グロブリンの精製 |
CA2756244A1 (en) | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
EP2417156B1 (en) | 2009-04-07 | 2015-02-11 | Roche Glycart AG | Trivalent, bispecific antibodies |
CN102448985B (zh) | 2009-05-27 | 2015-08-05 | 霍夫曼-拉罗奇有限公司 | 三或四特异性抗体 |
US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
TWI412375B (zh) | 2009-08-28 | 2013-10-21 | Roche Glycart Ag | 人類化抗cdcp1抗體 |
TW201113037A (en) | 2009-08-28 | 2011-04-16 | Hoffmann La Roche | Antibodies against CDCP1 for the treatment of cancer |
KR20120041247A (ko) | 2009-09-07 | 2012-04-30 | 에프. 호프만-라 로슈 아게 | 글리코실화의 분석을 위한 당펩티드의 es-ms |
CN104945509A (zh) | 2009-09-16 | 2015-09-30 | 弗·哈夫曼-拉罗切有限公司 | 包含卷曲螺旋和/或系链的蛋白质复合体及其用途 |
SI2516469T1 (sl) | 2009-12-22 | 2016-05-31 | Roche Glycart Ag | Protitelesa proti her3 in uporabe le-teh |
TW201138821A (en) | 2010-03-26 | 2011-11-16 | Roche Glycart Ag | Bispecific antibodies |
WO2012010582A1 (en) | 2010-07-21 | 2012-01-26 | Roche Glycart Ag | Anti-cxcr5 antibodies and methods of use |
JP5758004B2 (ja) | 2010-08-24 | 2015-08-05 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ジスルフィドによって安定化されたFv断片を含む二重特異性抗体 |
CA2809632A1 (en) | 2010-10-05 | 2012-04-12 | Monika Baehner | Antibodies against human tweak and uses thereof |
EP2655413B1 (en) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
MX341958B (es) * | 2011-02-23 | 2016-09-08 | Hoffmann La Roche | Anticuerpos contra el il33r humano y usos de los mismos. |
MX342034B (es) | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
BR112013019975A2 (pt) | 2011-02-28 | 2017-08-01 | Hoffmann La Roche | proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira" |
US20140271680A1 (en) | 2011-08-12 | 2014-09-18 | Universite Paris-Est Creteil Val De Marne | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
RU2014114119A (ru) | 2011-09-23 | 2015-10-27 | Рош Гликарт Аг | Биспецифические анти-egfr/анти igf-1r-антитела |
ES2548215T3 (es) | 2011-10-05 | 2015-10-14 | F. Hoffmann-La Roche Ag | Proceso para la producción de anticuerpos de la glicoforma G1 |
WO2013119966A2 (en) | 2012-02-10 | 2013-08-15 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
RU2014149681A (ru) | 2012-05-24 | 2016-07-20 | Ф. Хоффманн-Ля Рош Аг | Антитела с множественной специфичностью |
WO2014001325A1 (en) | 2012-06-27 | 2014-01-03 | F. Hoffmann-La Roche Ag | Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
JP6203838B2 (ja) | 2012-06-27 | 2017-09-27 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用 |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
EP3055329B1 (en) | 2013-10-11 | 2018-06-13 | F. Hoffmann-La Roche AG | Multispecific domain exchanged common variable light chain antibodies |
WO2015082446A1 (en) | 2013-12-02 | 2015-06-11 | F. Hoffmann-La Roche Ag | Treatment of cancer using an anti-cdcp1 antibody and a taxane |
UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
PL3227332T3 (pl) | 2014-12-03 | 2020-06-15 | F. Hoffmann-La Roche Ag | Wielospecyficzne przeciwciała |
WO2018106959A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
KR20210095165A (ko) | 2018-11-19 | 2021-07-30 | 프로제너티, 인크. | 바이오의약품으로 질환을 치료하기 위한 방법 및 디바이스 |
CN114901700A (zh) * | 2019-11-21 | 2022-08-12 | 尤尼蒂生物技术公司 | 针对tie-2的抗体及其使用方法 |
EP4309722A2 (en) | 2019-12-13 | 2024-01-24 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) * | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
US5204244A (en) * | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) * | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US6743594B1 (en) | 1995-06-06 | 2004-06-01 | Human Genome Sciences, Inc. | Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5) |
EP0975749A2 (en) | 1996-05-28 | 2000-02-02 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Cc chemokine receptor 5, antibodies thereto, transgenic animals |
US6528625B1 (en) | 1996-10-28 | 2003-03-04 | Millennium Pharmaceuticals, Inc. | Anti-CCR5 antibodies and kits comprising same |
ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
US20030099645A1 (en) | 2000-10-10 | 2003-05-29 | Lobo Peter Isaac | Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes |
US6610834B1 (en) * | 1998-11-18 | 2003-08-26 | Peter I. Lobo | Human IgM antibodies to chemokine receptors |
ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
JP2002538771A (ja) | 1998-12-16 | 2002-11-19 | プロジェニクス・ファーマスーティカルズ・インコーポレイテッド | Hiv−1の融合及び付着の相乗的阻害、そのための組成物および抗体 |
WO2000053633A2 (de) | 1999-03-11 | 2000-09-14 | Micromet Ag | Antikörper- und chemokinkonstrukte, die gegen ccr5 gerichtet sind, und ihre verwendung in der behandlung von autoimmunkrankheiten |
US20030049251A1 (en) * | 1999-12-08 | 2003-03-13 | Barbas Carlos F. | Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1 |
WO2001043779A2 (en) | 1999-12-16 | 2001-06-21 | Tanox, Inc. | Anti-hiv-1 conjugates for treatment of hiv disease |
JP2003523744A (ja) * | 2000-02-09 | 2003-08-12 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Ccr5に対する抗体 |
US20040043033A1 (en) * | 2000-05-01 | 2004-03-04 | Green Lorrence H. | Method and vaccine for the prevention of AIDS |
US7138119B2 (en) | 2000-09-15 | 2006-11-21 | Progenics Pharmaceuticals, Inc. | Compositions and methods for inhibition of HIV-1 infection |
US7005503B2 (en) * | 2002-02-08 | 2006-02-28 | Genetastix Corporation | Human monoclonal antibody against coreceptors for human immunodeficiency virus |
US20030165988A1 (en) | 2002-02-08 | 2003-09-04 | Shaobing Hua | High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins |
EP1207202A1 (en) | 2000-11-16 | 2002-05-22 | Mölling, Karin, Inst. für med. Virologie der Uni. Zürich | Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members |
US20020147147A1 (en) * | 2000-11-16 | 2002-10-10 | Karin Molling | Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members |
US7175988B2 (en) | 2001-02-09 | 2007-02-13 | Human Genome Sciences, Inc. | Human G-protein Chemokine Receptor (CCR5) HDGNR10 |
US20030003440A1 (en) | 2001-03-14 | 2003-01-02 | Lucia Lopalco | Novel CCR5 epitope and antibodies against it |
US20020146415A1 (en) | 2001-04-06 | 2002-10-10 | Olson William C. | Methods for inhibiting HIV-1 infection |
US7060273B2 (en) * | 2001-04-06 | 2006-06-13 | Progenics Pharmaceuticals, Inc. | Methods for inhibiting HIV-1 infection |
WO2003033666A2 (en) | 2001-10-16 | 2003-04-24 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes |
AU2003209059A1 (en) | 2002-02-08 | 2003-09-02 | Genetastix Corporation | Human monoclonal antibodies against membrane proteins |
US7122185B2 (en) | 2002-02-22 | 2006-10-17 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
EP2058006A1 (en) | 2002-02-22 | 2009-05-13 | Progenics Pharmaceuticals, Inc. | Anti-CCR5 antibody |
-
2006
- 2006-03-29 TW TW095110965A patent/TW200720289A/zh unknown
- 2006-03-30 AR ARP060101255A patent/AR052959A1/es not_active Application Discontinuation
- 2006-03-31 US US11/394,439 patent/US7615216B2/en not_active Expired - Fee Related
- 2006-03-31 CA CA002603692A patent/CA2603692A1/en not_active Abandoned
- 2006-03-31 EP EP06723934A patent/EP1869087A2/en not_active Withdrawn
- 2006-03-31 RU RU2007139953/13A patent/RU2007139953A/ru not_active Application Discontinuation
- 2006-03-31 AU AU2006228663A patent/AU2006228663A1/en not_active Abandoned
- 2006-03-31 CN CNA2006800170650A patent/CN101175771A/zh active Pending
- 2006-03-31 SG SG200901861-5A patent/SG151284A1/en unknown
- 2006-03-31 WO PCT/EP2006/002974 patent/WO2006103100A2/en active Application Filing
- 2006-03-31 MX MX2007011842A patent/MX2007011842A/es not_active Application Discontinuation
- 2006-03-31 KR KR1020077024197A patent/KR20070116136A/ko not_active Application Discontinuation
- 2006-03-31 BR BRPI0609792-8A patent/BRPI0609792A2/pt not_active IP Right Cessation
- 2006-03-31 JP JP2008503436A patent/JP4733736B2/ja not_active Expired - Fee Related
- 2006-03-31 EP EP10191497A patent/EP2336183A3/en not_active Withdrawn
-
2007
- 2007-09-19 IL IL186071A patent/IL186071A0/en unknown
- 2007-09-24 CR CR9393A patent/CR9393A/es not_active Application Discontinuation
- 2007-09-25 NO NO20074867A patent/NO20074867L/no not_active Application Discontinuation
- 2007-09-27 MA MA30257A patent/MA29374B1/fr unknown
- 2007-09-28 ZA ZA200708332A patent/ZA200708332B/xx unknown
-
2010
- 2010-10-25 JP JP2010238172A patent/JP2011079836A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2006228663A1 (en) | 2006-10-05 |
ZA200708332B (en) | 2009-04-29 |
US20070036796A1 (en) | 2007-02-15 |
RU2007139953A (ru) | 2009-05-10 |
US7615216B2 (en) | 2009-11-10 |
JP2011079836A (ja) | 2011-04-21 |
CR9393A (es) | 2008-02-20 |
EP2336183A2 (en) | 2011-06-22 |
TW200720289A (en) | 2007-06-01 |
EP1869087A2 (en) | 2007-12-26 |
MX2007011842A (es) | 2007-10-11 |
WO2006103100A2 (en) | 2006-10-05 |
CN101175771A (zh) | 2008-05-07 |
CA2603692A1 (en) | 2006-10-05 |
JP2008533998A (ja) | 2008-08-28 |
WO2006103100A3 (en) | 2006-12-28 |
MA29374B1 (fr) | 2008-04-01 |
BRPI0609792A2 (pt) | 2010-04-27 |
KR20070116136A (ko) | 2007-12-06 |
NO20074867L (no) | 2007-12-07 |
EP2336183A3 (en) | 2011-10-12 |
JP4733736B2 (ja) | 2011-07-27 |
IL186071A0 (en) | 2008-01-20 |
SG151284A1 (en) | 2009-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR052959A1 (es) | Anticuerpos anti- ccr5 y usos de los mismos | |
PE20120079A1 (es) | Moleculas de anticuerpos mejoradas | |
AR123876A2 (es) | Composición farmacéutica de anticuerpos anti-cgrp | |
CO2018013500A2 (es) | Anticuerpos anti-pd-l1 y usos de los mismos | |
AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
PE20191102A1 (es) | Anticuerpos anti-pd-1 y sus usos | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
PE20191208A1 (es) | Anticuerpos anti-cd73 y usos de los mismos | |
PE20110797A1 (es) | Anticuerpos anti mn | |
ES2523194T3 (es) | Anticuerpo monoclonal humano específico para cada tumor | |
CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
PE20120899A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b | |
RU2017145268A (ru) | Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов | |
PE20110802A1 (es) | Un anticuerpo antagonista de pcsk9 | |
AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
PE20190261A1 (es) | Anticuerpos que reconocen tau | |
JP2013198490A5 (es) | ||
RS54393B1 (en) | HUMAN MONOCLONAL ANTIBODIES ON KINASE-1 SIMILAR TO ACTIVE RECEPTOR | |
PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
PE20190970A1 (es) | Anticuerpos anti-cd40 y sus usos | |
NZ595235A (en) | Compositions and methods for increasing muscle growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |